Disorders of phosphate metabolism in chronic renal disease

Current Opinion in Pharmacology

Volumn 2, Issue 2, 2002, Pages 171-176

  Edwards, Richard M ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ADENOSINE TRIPHOSPHATASE; ALLYLAMINE DERIVATIVE; ALUMINUM HYDROXIDE; CALCIFEDIOL; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM PHOSPHATE; CALCIUM SENSING RECEPTOR; CARRIER PROTEIN; CHOLESTEROL; COLECALCIFEROL; CREATININE; DIVALENT CATION; DOXERCALCIFEROL; FOSCARNET; G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; HYDROLASE; IRON DERIVATIVE; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; SEVELAMER; SODIUM ION; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DEMENTIA; DIET RESTRICTION; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INTESTINE ABSORPTION; KIDNEY TUBULE ABSORPTION; MYOPATHY; NONHUMAN; OSTEOMALACIA; PATHOGENESIS; PHOSPHATE EXCRETION; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SOFT TISSUE CALCIFICATION;

EID: 0036534564     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00137-6     Document Type: Review

References (48)

1. Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine
2. Cloning and functional characterization of a sodium-dependent phosphate transporter expressed in human lung and small intestine
3. Expression cloning of human and rat renal cortex Na/Pi cotransport
4. Proximal tubular phosphate reabsorption: Molecular mechanisms
5. Evolution of the Na-Pi cotransport system
6. Regulation of small intestinal Na-Pi type IIb cotransporter by dietary phosphate intake
7. On the pathogenesis of the uremic state
8. 'Magnification phenomenon' in chronic renal disease
9. Secondary hyperparathyroidism in renal failure: The trade-off hypothesis revisited
10. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management
11. Detection and quantification of cardiovascular calcifications with electron beam tomography to estimate risk in hemodialysis patients
12. 2+ and other ions as extracellular (first) messengers
13. Phosphorus restriction prevents parathyroid cell growth in uremic rats. High phosphorus directly stimulates PTH secretion in vitro
14. Parathyroid hormone gene expression in hypophosphatemia rats
15. Direct effects of phosphorus on parathyroid hormone secretion from whole rat parathyroid glands in vitro
16. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo
17. Vitamin D and calcium transport
18. Hyperphosphatemia: Pharmacologic intervention yesterday, today and tomorrow
19. Hyperphosphatemia in end-stage renal disease patients: Pathophysiological consequences
20. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients
21. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study
22. Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism
23. Parathyroid hormone, vitamin D and cardiovascular disease in chronic renal failure
24. Phosphate depletion arrests progression of chronic renal failure independent of protein intake
25. Preservation of renal function in experimental glomerulonephritis
26. Effects of dietary protein and phosphorus restriction on the progress of early renal failure
27. Restricted phosphorus and nitrogen intake to slow the progression of chronic renal failure: A controlled trial
28. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism
29. Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease
30. Effect of RenaGel®, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats
31. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients
32. RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid homone
33. New phosphate binding agents: Ferric compounds
34. Phosphate binders on iron basis: A new perspective?
35. Use of phosphonocarboxylic acids as inhibitors of sodium-phosphate cotransport
36. Mechanism of phosphaturia elicited by administration of phosphonoformate in vivo
37. Phosphate excretion and phosphate transporter messenger RNA in uremic rats treated with phosphonoformic acid
38. Use of phosphonoformic acid to induce phosphaturia in chronic renal failure in rats
39. 2+ sensing receptor from bovine parathyroid
40. Calcium-sensing receptor and calcimimetic agents
41. Calcimimetics with potent and selective activity on the parathyroid calcium receptor
42. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats
43. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism
44. Parathyroid hormone suppression by intravenous 1, 25 dihydroxyvitamin D. A role for increased sensitivity to calcium
45. 3
46. 2 (paricalcitol) safety and effectively reduces the levels of intact PTH in patients on hemodialysis
47. 2 is safe and effective for the suppression of secondary hyperparathyroidism in haemodialysis patients
48. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion